Otonomy Announces Pricing of $60.1 Million Public Offering
July 09, 2020 09:00 ET
|
Otonomy, Inc.
SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Announces Proposed Public Offering
July 08, 2020 16:03 ET
|
Otonomy, Inc.
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
July 06, 2020 16:04 ET
|
Otonomy, Inc.
OTO-313 demonstrated a higher proportion of responders than placeboGiven clear signal in this proof of concept study, Otonomy plans to advance OTO-313 to full Phase 2 development in tinnitusOTO-313...
Otonomy Provides Update on Clinical Trials and Development Programs
June 15, 2020 16:05 ET
|
Otonomy, Inc.
Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020Results from Phase 1/2 trial of...
Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
June 11, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
June 10, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Host Pipeline Program Update Conference Call and Webcast
June 08, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
Otonomy Provides Business Update Related to COVID-19 Pandemic
April 09, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a...
AMERICAN TINNITUS ASSOCIATION GIVES FREE ACCESS TO NEW MENTAL HEALTH AND WELLNESS MAGAZINE
April 02, 2020 10:15 ET
|
American Tinnitus Association
Vienna, VA, April 02, 2020 (GLOBE NEWSWIRE) -- The American Tinnitus Association is giving free access to its Spring 2020 digital issue of Tinnitus Today magazine – “Tinnitus in a Time of Chaos.”...